Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Eledon Pharmaceuticals, Inc. Market Cap
From what 6 stock analysts predict, the share price for Eledon Pharmaceuticals, Inc. (ELDN) might increase by 157.73% in the next year. This is based on a 12-month average estimation for ELDN. Price targets go from $7 to $20.5. The majority of stock analysts believe ELDN is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
About 6 Wall Street analysts have assignedELDN 6 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect Eledon Pharmaceuticals, Inc. to buy. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on ELDN. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of ELDN.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Vernon Bernardino HC Wainwright & Co. | Buy | $16 | Reiterates | Nov 20, 2024 |
| Vernon Bernardino HC Wainwright & Co. | Buy | $16 | Reiterates | Jun 4, 2024 |
| Vernon Bernardino HC Wainwright & Co. | Buy | $16 | Reiterates | May 10, 2024 |
| Vernon Bernardino HC Wainwright & Co. | Buy | $16 | Maintains | May 7, 2024 |
| Vernon Bernardino HC Wainwright & Co. | Buy | $13 | Reiterates | Mar 22, 2024 |
| Vernon Bernardino HC Wainwright & Co. | Buy | $13 | Reiterates | Nov 13, 2023 |
| Vernon Bernardino HC Wainwright & Co. | Buy | $13 | Maintains | Oct 24, 2023 |
| Robert LeBoyer Noble Capital Markets | Outperform | $10 | Initiates | Sep 27, 2023 |
| Alethia Young Cantor Fitzgerald | Overweight | $9 | Reiterates | Aug 22, 2023 |
| Vernon Bernardino HC Wainwright & Co. | Buy | $25 | Reiterates | May 26, 2023 |
| Thomas Smith SVB Leerink | Outperform | $26 | Maintains | Jun 1, 2022 |
| Vernon Bernardino HC Wainwright & Co. | Buy | $25 | Maintains | Nov 24, 2021 |
| Thomas Smith SVB Leerink | Outperform | $33 | Maintains | Apr 27, 2021 |
Cantor Fitzgerald | Overweight | Initiates | Mar 23, 2021 | |
SVB Leerink | Outperform | Initiates | Feb 8, 2021 |
When did it IPO
2014
Staff Count
20
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. David-Alexandre C. Gros M.D., Ph.D.
Market Cap
$274.8M
In 2023, ELDN generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that ELDN's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Tue, 12 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Eledon Pharmaceuticals completed enrollment of the Phase 2 BESTOW trial ahead of schedule, with topline results expected in Q4 2025. They also reported positive initial data for tegoprubart in diabetes. The company raised $85 million in an oversubscribed offering to extend its cash runway to late 2026.
Why It Matters - Eledon Pharmaceuticals accelerated trial progress and positive early data, boosting investor confidence. The successful funding extends operational viability, enhancing growth potential and stock value.
Tue, 29 Oct 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Eledon Pharmaceuticals announced positive results from a study of tegoprubart in islet transplant recipients, showing higher engraftment rates and insulin independence in early subjects.
Why It Matters - Positive results from Eledon Pharmaceuticals' tegoprubart trial could enhance its market position in diabetes treatment, potentially boosting stock value and attracting investor interest.
Tue, 29 Oct 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Eledon Pharmaceuticals priced an underwritten offering of 18.4 million shares at $3.65 each and pre-funded warrants for 4.9 million shares at $3.649 each.
Why It Matters - Eledon Pharmaceuticals' stock offering dilutes existing shares, potentially impacting share value. The pricing indicates market confidence or need for capital, influencing investor sentiment.
Tue, 29 Oct 2024
Sentiment - POSITIVE
Source - Seeking Alpha
Summary - Phase 1b data for tegoprubart shows promise in preventing organ rejection in kidney transplants. Phase 2 results expected in Q4 2025; organ transplant drug market projected at $6.4 billion by 2030.
Why It Matters - Positive phase 1b results for tegoprubart enhance its market potential in a growing $6.4 billion organ transplant immunosuppressant market, indicating strong future investment opportunities.
Wed, 11 Sep 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Eledon Pharmaceuticals (NASDAQ: ELDN) announced a leadership change with David-Alexandre C. appointed, as reported on September 11, 2024.
Why It Matters - Eledon Pharmaceuticals' announcement of a key executive could signal strategic changes or new initiatives, impacting investor sentiment and stock performance.
Wed, 04 Sep 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Eledon has completed enrollment in its Phase 2 BESTOW clinical trial for Tegoprubart, aimed at preventing organ rejection in kidney transplants.
Why It Matters - Completion of enrollment in Eledon's Phase 2 trial for Tegoprubart could indicate progress in kidney transplant therapies, potentially influencing stock performance and market confidence.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
